• Investors may be wondering whether PACS Group at around US$35.97 is still offering value after its strong run, or if the easy gains are already behind it.
• The stock has moved 11.9% over the last 7 days and 5.3% over the last 30 days, while the 1 year return of 286.8% contrasts with a year to date return of a 9.0% decline.
• Recent attention on PACS Group has centered on its strong 1 year share price performance and the healthcare services segment it operates in. This has made the stock more visible to both new and existing shareholders. This backdrop helps explain why short term price swings are attracting more interest from investors who are now asking whether the fundamentals justify the current level.
• PACS Group currently has a valuation score of 3/6. The next sections will compare what different valuation approaches indicate about that score and then finish with a broader way to think about value beyond the usual ratios.

PACS Group delivered 286.8% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Approach 1: PACS Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash PACS Group is expected to generate in the future and then discounts those cash flows back to today to estimate what the business might be worth right now.

PACS Group reports last twelve months free cash flow of about $312.1 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates project free cash flow reaching $590.9 million in 2035, with specific forecasts such as $417.9 million in 2028. Simply Wall St provides analyst inputs for the nearer years and then extends those trends further out to build a ten year cash flow profile.

Based on these projections, the DCF model arrives at an estimated intrinsic value of about $75.72 per share. Compared with the recent share price around $35.97, the model suggests PACS Group trades at a 52.5% discount, which indicates that the shares may currently be undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests PACS Group is undervalued by 52.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for PACS Group.

Approach 2: PACS Group Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. This makes it a practical cross check against the DCF result you just saw.

What counts as a "normal" P/E depends a lot on how the market views a company’s growth prospects and risk. Higher expected growth and lower perceived risk can support a higher P/E, while slower growth or higher risk usually points to a lower, more cautious multiple.

PACS Group currently trades on a P/E of 29.51x. That sits above both the Healthcare industry average of 22.60x and a peer average of 23.40x. Simply Wall St also calculates a Fair Ratio of 22.66x, which is the P/E that might be expected after considering factors such as the company’s earnings growth profile, its industry, profit margins, market cap and specific risks.

This Fair Ratio is more tailored than a simple peer or industry comparison because it blends those fundamentals into a single yardstick rather than relying on broad group averages.

Since PACS Group’s actual P/E of 29.51x is higher than the Fair Ratio of 22.66x, the shares look expensive on this earnings based view.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your PACS Group Narrative

Earlier the focus was on ratios and models. Now you can go a step further by using Narratives on Simply Wall St’s Community page. There you set out your own story for PACS Group, link that story to specific assumptions for revenue, earnings and margins, and see an implied fair value that you can compare to the current price. The Narrative then refreshes automatically when new data such as PACS Group’s analyst targets, earnings or news arrive. For example, one investor who aligns with the higher analyst target of US$40 and assumes stronger margin expansion may see more upside than another investor who leans toward the US$32 target and a lower P/E. Both can clearly see how their different views translate into different fair values and potential buy or sell decisions.

Do you think there's more to the story for PACS Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.